Predicting which HIV patients will respond better to future therapeutic vaccine

A new study suggests that HIV patients with a higher level of a particular biomarker, or a measurable indicator found in the blood, may respond more favourably to an experimental immune activating vaccine.

Experts at St George's, University of London, and Norwegian company, Bionor Pharma Researchers, believe the findings might lead to a more customised vaccine for certain , which potentially might permit them to come off antiretrovirals, drugs used to treat HIV.

The research found that the , Vacc-4x, reduced the amount of virus circulating in the body by more than half in patients with higher levels of the particular biomarker compared to those with lower levels.

Professor Angus Dalgleish, of St George's, University of London, said: "In spite of very effective drugs against HIV these need to be taken daily and have significant side-effects.

"The ability to replace this daily medication with a vaccine that allows several months of being off medication, not to mention the enormous financial gains that would be delivered to health services, is a step closer with these preliminary results."

Further study will be needed to confirm the results.

These new results were announced today (July 18) at the AIDS 2014 Conference in Melbourne, Australia.

The results come from a collaborative project between St George's, University of London and Bionor Pharma.

In the UK nearly 78,000 people were receiving specialist care for HIV in 2012.

add to favorites email to friend print save as pdf

Related Stories

Spanish hospital to trial new HIV treatment

Dec 09, 2013

Researchers at a Spanish hospital announced Monday they will start trials next year of a therapeutic vaccine for patients who already have HIV, the virus that causes AIDS.

Durable end to AIDS will require HIV vaccine development

Feb 05, 2014

Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately ...

Recommended for you

Withdrawal from the evolutionary race

8 hours ago

In some HIV sufferers, the immune system does not fight off the immune deficiency virus. Instead, the body tolerates the pathogen. A research team headed by ETH Zurich has now determined how strongly patients ...

The genetics of coping with HIV

Sep 16, 2014

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

Long acting HIV drugs to be developed

Sep 11, 2014

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of 'pill fatigue'.

User comments